Combination therapy for treatment of osteoporosis: A review
Combination therapy for treatment of osteoporosis: A review
复制标题
DOI：
10.1016/j.ajog.2007.07.022
复制
发表时间：
2007-12-01
影响因子：
9.8
通讯作者：
Dalkin, Alan C.
中科院分区：
文献类型：
--
作者：
Pinkerton, JoAnn V.;Dalkin, Alan C.
骨质疏松症的联合治疗已经在短期的小型试验中用各种组合进行了测试。通过 Medline 确定了相关的人类和动物随机临床试验数据，并对其进行了审查，重点关注不同类型联合疗法的风险和益处。在某些（但不是全部）组合中发现骨密度有所改善。没有足够长度或数量的大型试验来确定骨折疗效。如果单一疗法不成功，如果建议的联合疗法具有额外的非骨骼益处，或者使用合成代谢剂，然后使用抗吸收剂进行序贯治疗，则考虑联合疗法。尽管联合治疗总体上因成本、对骨潜在过度抑制的担忧以及缺乏长期安全性和骨折疗效而存在局限性，但选定的患者可能会受益。
Combination therapy for osteoporosis has been tested in small trials of short duration with various combinations. Pertinent human and animal randomized clinical trial data were identified through Medline and reviewed with a focus on the risks and benefits of different types of combination therapies. Improvements in bone density were found in some, but not all, combinations. There are no large trials of adequate length or numbers to determine fracture efficacy. Consider combination therapy if monotherapy is unsuccessful, if there is an added nonskeletal benefit to the proposed combination or as sequential treatment with an anabolic agent followed by an antiresorptive agent. Although combination therapy, in general, has limitations based on cost, concern about potential oversuppression of bone, and lack of long-term safety and fracture efficacy, selected patients may benefit.